Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis

Efforts to improve the clinical outcome of highly aggressive triple-negative breast cancer (TNBC) have been hindered by the lack of effective targeted therapies. Thus, it is important to identify the specific gene targets/pathways driving the invasive phenotype to develop more effective therapeutics...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 110; no. 27; pp. 11121 - 11126
Main Authors Lee, Shuet Theng, Feng, Min, Wei, Yong, Li, Zhimei, Qiao, Yuanyuan, Guan, Peiyong, Jiang, Xia, Wong, Chew Hooi, Huynh, Kelly, Wang, Jinhua, Li, Juntao, Karuturi, K. Murthy, Tan, Ern Yu, Hoon, Dave S. B., Kang, Yibin, Yu, Qiang
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 02.07.2013
National Acad Sciences
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Efforts to improve the clinical outcome of highly aggressive triple-negative breast cancer (TNBC) have been hindered by the lack of effective targeted therapies. Thus, it is important to identify the specific gene targets/pathways driving the invasive phenotype to develop more effective therapeutics. Here we show that ubiquitin-associated and SH3 domain-containing B (UBASH3B), a protein tyrosine phosphatase, is overexpressed in TNBC, where it supports malignant growth, invasion, and metastasis largely through modulating epidermal growth factor receptor (EGFR). We also show that UBASH3B is a functional target of anti-invasive microRNA 200a (miR200a) that is down-regulated in TNBC. Importantly, the oncogenic potential of UBASH3B is dependent on its tyrosine phosphatase activity, which targets CBL ubiquitin ligase for dephosphorylation and inactivation, leading to EGFR up-regulation. Thus, UBASH3B may function as a crucial node in bridging multiple invasion-promoting pathways, thereby providing a potential therapeutic target for TNBC.
Bibliography:http://dx.doi.org/10.1073/pnas.1300873110
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by Carlos L. Arteaga, Vanderbilt University School of Medicine, Nashville, TN, and accepted by the Editorial Board May 20, 2013 (received for review January 29, 2013)
Author contributions: S.T.L., M.F., Y.W., D.S.B.H., Y.K., and Q.Y. designed research; S.T.L., M.F., Y.W., Z.L., Y.Q., P.G., X.J., C.H.W., K.H., J.W., and Q.Y. performed research; S.T.L., M.F., K.M.K., E.Y.T., D.S.B.H., and Y.K. contributed new reagents/analytic tools; S.T.L., M.F., Y.W., Z.L., Y.Q., P.G., X.J., C.H.W., K.H., J.W., J.L., D.S.B.H., Y.K., and Q.Y. analyzed data; and S.T.L. and Q.Y. wrote the paper.
1S.T.L., M.F., and Y.W. contributed equally to this work.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1300873110